{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T05:33:57Z","timestamp":1736228037891,"version":"3.32.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2006,1,10]],"date-time":"2006-01-10T00:00:00Z","timestamp":1136851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2006,1,10]],"date-time":"2006-01-10T00:00:00Z","timestamp":1136851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2006,5,1]]},"DOI":"10.1038\/sj.tpj.6500359","type":"journal-article","created":{"date-parts":[[2006,1,10]],"date-time":"2006-01-10T06:04:36Z","timestamp":1136873076000},"page":"211-219","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["The role of Gilbert's syndrome and frequent NAT2 slow acetylation polymorphisms in the pharmacokinetics of retigabine"],"prefix":"10.1038","volume":"6","author":[{"given":"R","family":"Hermann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Borlak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U","family":"Munzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Niebch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U","family":"Fuhr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Maus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Erb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,1,10]]},"reference":[{"key":"BF6500359_CR1","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1053\/jhep.2000.18193","volume":"32","author":"J Borlak","year":"2000","unstructured":"Borlak J, Thum T, Landt O, Erb K, Hermann R . Molecular diagnosis of a familial non haemolytic hyperbilirubinemia (Gilbert's syndrome) in healthy subjects. Hepatology 2000; 32: 792\u2013795.","journal-title":"Hepatology"},{"key":"BF6500359_CR2","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1056\/NEJM199511023331802","volume":"333","author":"PJ Bosma","year":"1995","unstructured":"Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, Oostra BA et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 1995; 333: 1171\u20131175.","journal-title":"N Engl J Med"},{"key":"BF6500359_CR3","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S0140-6736(96)91273-8","volume":"347","author":"G Monaghan","year":"1996","unstructured":"Monaghan G, Ryan M, Seddon R, Hume R, Burchell B . Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet 1996; 347: 578\u2013581.","journal-title":"Lancet"},{"key":"BF6500359_CR4","doi-asserted-by":"publisher","first-page":"8170","DOI":"10.1073\/pnas.95.14.8170","volume":"95","author":"E Beutler","year":"1998","unstructured":"Beutler E, Geleart T, Demina A . Racial variability in the UDP-glucuronyltransferase 1 (UGT1A1) promotor: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Sci USA 1998; 95: 8170\u20138174.","journal-title":"Proc Natl Sci USA"},{"key":"BF6500359_CR5","first-page":"593","volume":"3","author":"P Radu","year":"2001","unstructured":"Radu P, Atsmon J . Gilbert's syndrome \u2013 clinical and pharmacological implications. Isr Med Assoc J 2001; 3: 593\u2013598.","journal-title":"Isr Med Assoc J"},{"key":"BF6500359_CR6","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1023\/A:1008261821434","volume":"8","author":"E Wasserman","year":"1997","unstructured":"Wasserman E, Myara A, Lokiec F, Goldwasser F, Trivin F, Mahjoubi M et al. Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. Ann Oncol 1997; 8: 1049\u20131051.","journal-title":"Ann Oncol"},{"key":"BF6500359_CR7","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/sj.tpj.6500072","volume":"2","author":"L Iyer","year":"2002","unstructured":"Iyer L, Das S, Janisch L, Wen M, Ramirez J, Karrison T et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002; 2: 43\u201347.","journal-title":"Pharmacogenomics J"},{"key":"BF6500359_CR8","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/BF02353477","volume":"24","author":"SP Spielberg","year":"1996","unstructured":"Spielberg SP . N-acetyltransferases: pharmacogenetics and clinical consequences of polymorphic drug metabolism. J Pharmacokinet Biopharm 1996; 24: 509\u2013519.","journal-title":"J Pharmacokinet Biopharm"},{"key":"BF6500359_CR9","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1046\/j.1365-2796.2001.00879.x","volume":"250","author":"M Ingelmann-Sundberg","year":"2001","unstructured":"Ingelmann-Sundberg M . Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J Int Med 2001; 250: 186\u2013200.","journal-title":"J Int Med"},{"key":"BF6500359_CR10","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1177\/0091270003256065","volume":"43","author":"TD Bjornsson","year":"2003","unstructured":"Bjornsson TD, Wagner JA, Donahue SR, Harper D, Karim A, Khouri MS et al. A review and assessment of potential sources of ethnic differences in drug responsiveness. J Clin Pharmacol 2003; 43: 943\u2013967.","journal-title":"J Clin Pharmacol"},{"key":"BF6500359_CR11","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/0920-1211(95)00101-8","volume":"23","author":"A Rostock","year":"1996","unstructured":"Rostock A, Tober C, Rundfeldt C, Bartsch R, Engel J, Polymeropoulos EE et al. D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures. Epilepsy Res 1996; 23: 211\u2013223.","journal-title":"Epilepsy Res"},{"key":"BF6500359_CR12","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/0014-2999(96)00073-8","volume":"303","author":"C Tober","year":"1996","unstructured":"Tober C, Rostock A, Rundfeldt C, Bartsch R . D-23129: a potent anticonvulsant in the amygdala kindling model of complex partial seizures. Eur J Pharmacol 1996; 303: 163\u2013169.","journal-title":"Eur J Pharmacol"},{"key":"BF6500359_CR13","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/PL00005320","volume":"359","author":"V Armand","year":"1999","unstructured":"Armand V, Rundfeldt C, Heinemann U . Effects of retigbine (D-23129) on different patterns of epileptiform activity induced by 4-aminopyridine in rat entorhinal cortex hippocampal slices. Naunyn Schmiedebergs Arch Pharmacol 1999; 359: 33\u201339.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"BF6500359_CR14","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/j.1528-1157.2000.tb01501.x","volume":"41","author":"V Armand","year":"2000","unstructured":"Armand V, Rundfeldt C, Heinemann U . Effects of retigabine (D-23129) on different patterns of epileptiform activity induced by low magnesium in rat entorhinal cortex hippocampal slices. Epilepsia 2000; 41: 28\u201333.","journal-title":"Epilepsia"},{"key":"BF6500359_CR15","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1126\/science.282.5395.1890","volume":"282","author":"HS Wang","year":"1998","unstructured":"Wang HS, Pan Z, Shi W, Brown BS, Wymore RS, Cohen US et al. KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel. Science 1998; 282: 1890\u20131893.","journal-title":"Science"},{"key":"BF6500359_CR16","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0304-3940(00)00866-1","volume":"281","author":"C Rundfeldt","year":"2000","unstructured":"Rundfeldt C, Netzer R . The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells transfected with human KCNQ2\/3 subunits. Neuroscie Lett 2000; 281: 73\u201376.","journal-title":"Neuroscie Lett"},{"key":"BF6500359_CR17","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1124\/mol.58.2.253","volume":"58","author":"MJ Main","year":"2000","unstructured":"Main MJ, Cryan JE, Dupere JR, Cox B, Clare JJ, Burbidge SA et al. Modulation KCNQ2\/3 potassium channels by the novel anticonvulsant retigabine. Mol Pharmacol 2000; 58: 253\u2013262.","journal-title":"Mol Pharmacol"},{"key":"BF6500359_CR18","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1124\/mol.58.3.591","volume":"58","author":"AD Wickenden","year":"2000","unstructured":"Wickenden AD, Yu WF, Zou AR, Jegla T, Wagoner PK . Retigabine, a novel anti-convulsant, enhances activation of KCNQ2\/Q3 potassium channels. Mol Pharmacol 2000; 58: 591\u2013600.","journal-title":"Mol Pharmacol"},{"key":"BF6500359_CR19","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/sj.bjp.0703861","volume":"132","author":"AD Wickenden","year":"2001","unstructured":"Wickenden AD, Zou AR, Wagoner PK, Jegla T . Characterization of KCNQ5\/Q3 potassium channels expressed in mammalian cells. Br J Pharmacol 2001; 132: 381\u2013384.","journal-title":"Br J Pharmacol"},{"key":"BF6500359_CR20","first-page":"1063","volume":"50","author":"C Rundfeldt","year":"2000","unstructured":"Rundfeldt C, Netzer R . Investigation into the mechanism of action of the new anticonvulsant retigabine: interaction with GABAergic and glutamatergic neuro-transmission and with voltage gated Na+ and Ca2+ channels. Arzneimittelforsch\/Drug Res 2000; 50: 1063\u20131070.","journal-title":"Arzneimittelforsch\/Drug Res"},{"key":"BF6500359_CR21","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/j.1527-3458.1996.tb00304.x","volume":"2","author":"IM Kapetanovic","year":"1996","unstructured":"Kapetanovic IM, Rundfeldt C . A new anticonvulsant compound. CNS Drug Rev 1996; 2: 308\u2013321.","journal-title":"CNS Drug Rev"},{"key":"BF6500359_CR22","first-page":"36","volume":"51","author":"R Hermann","year":"2002","unstructured":"Hermann R, Schneider E, Menth M, Knebel N, Ferron GM, Borlak J et al. Retigabine. In: Bialer M, Johannessen S, Kupferberg H, Levy R, Loiseau P, Perucca E (eds). Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI); Epilepsy Res 2002; 51: 36\u201338.","journal-title":"Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI); Epilepsy Res"},{"key":"BF6500359_CR23","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1080\/004982597240424","volume":"27","author":"PJ McNeilly","year":"1997","unstructured":"McNeilly PJ, Torchin CD, Anderson LW, Kapetanovic IM, Kupferberg HJ, Strong JM . In vitro glucuronidation of D-23129, a new anticonvulsant, by human liver microsomes and liver slices. Xenobiotica 1997; 27: 431\u2013441.","journal-title":"Xenobiotica"},{"key":"BF6500359_CR24","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0090-9556(24)15258-0","volume":"27","author":"R Hempel","year":"1999","unstructured":"Hempel R, Schupke H, McNeilly PJ, Heinecke K, Kronbach C, Grunwald C et al. Metabolism of retigabine (D-23129), a novel anticonvulsant. Drug Metab Dispos 1999; 27: 613\u2013622.","journal-title":"Drug Metab Dispos"},{"key":"BF6500359_CR25","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0090-9556(24)15257-9","volume":"27","author":"A Hiller","year":"1999","unstructured":"Hiller A, Nguyen N, Strassburg CP, Li Q, Jainta H, Pechstein B et al. Retigabine N-glucuronidation and its potential role in enterohepatic circulation. Drug Metab Dispos 1999; 27: 605\u2013612.","journal-title":"Drug Metab Dispos"},{"doi-asserted-by":"crossref","unstructured":"Borlak J, Gasparic A, Locher M, Schupke H, Hermann R . N-glucuronidation of the antiepileptic drug retigabine: results from studies with human volunteers, heterologous expressed human UGTs, human liver, kidney and liver microsomal membranes of Crigler-Najjar Type II. Metabolism 2005; 54, in press.","key":"BF6500359_CR26","DOI":"10.1016\/j.metabol.2006.01.006"},{"key":"BF6500359_CR27","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1067\/mcp.2003.12","volume":"73","author":"R Hermann","year":"2003","unstructured":"Hermann R, Ferron GM, Erb K, Knebel N, Ruus P, Paul J et al. Effects of age and sex on the disposition of retigabine. Clin Pharmacol Ther 2003; 73: 61\u201370.","journal-title":"Clin Pharmacol Ther"},{"key":"BF6500359_CR28","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s00228-003-0558-6","volume":"58","author":"R Hermann","year":"2003","unstructured":"Hermann R, Knebel N, Niebch G, Paul J, Richards L, Borlak J et al. Pharmacokinetic interaction between retigabine and lamotrigine in healthy subjects. Eur J Clin Pharmacol 2003; 58: 795\u2013802.","journal-title":"Eur J Clin Pharmacol"},{"key":"BF6500359_CR29","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1177\/00912700222011210","volume":"42","author":"GM Ferron","year":"2002","unstructured":"Ferron GM, Paul J, Fruncillo R, Richards L, Knebel N, Getsy J et al. Multiple-dose, linear, dose-proportional pharmacokinetics of retigabine in healthy volunteers. J Clin Pharmacol 2002; 42: 175\u2013182.","journal-title":"J Clin Pharmacol"},{"key":"BF6500359_CR30","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S0022-3565(24)35227-9","volume":"291","author":"NL Benowitz","year":"1999","unstructured":"Benowitz NL, Perez-Stable EJ, Fong I, Modin G, Herrera B, Jacob III P . Ethnic differences in N-glucuronidation of nicotine and cotinine. J Pharmacol Exp Ther 1999; 291: 1196\u20131203.","journal-title":"J Pharmacol Exp Ther"},{"key":"BF6500359_CR31","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1046\/j.1365-2125.2003.01866.x","volume":"56","author":"C Skarke","year":"2003","unstructured":"Skarke C, Schmidt H, Geisslinger G, Darimont J, Loetsch J . Pharmacokinetics of morphine are not altered in subjects with Gilbert's syndrome. Br J Clin Pharmacol 2003; 56: 228\u2013231.","journal-title":"Br J Clin Pharmacol"},{"key":"BF6500359_CR32","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s00228-002-0490-1","volume":"58","author":"M Holthe","year":"2002","unstructured":"Holthe M, Klepstad P, Zahlsen K, Borchgrevink PC, Hagen L, Dale O et al. Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapy. Eur J Clin Pharmacol 2002; 58: 353\u2013356.","journal-title":"Eur J Clin Pharmacol"},{"key":"BF6500359_CR33","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/BF03190005","volume":"24","author":"A Esteban","year":"1999","unstructured":"Esteban A, Perez-Mateo M . Heterogeneity of paracetamol metabolism in Gilbert's syndrome. Eur J Drug Metab Pharmacokinet 1999; 24: 9\u201313.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"BF6500359_CR34","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0022-3565(24)29222-3","volume":"299","author":"MH Court","year":"2001","unstructured":"Court MH, Duan SX, von Moltke LL, Greenblatt DJ, Patten CJ, Miners JO et al. Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronyltransferase isoforms. J Pharmacol Exp Ther 2001; 299: 998\u20131006.","journal-title":"J Pharmacol Exp Ther"},{"key":"BF6500359_CR35","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1002\/j.1552-4604.1994.tb01969.x","volume":"34","author":"RJ Herman","year":"1994","unstructured":"Herman RJ, Chaudhary A, Szakacs CB . Disposition of lorazepam in Gilbert's syndrome: effects of fasting, feeding, and enterohepatic circulation. J Clin Pharmacol 1994; 34: 978\u2013984.","journal-title":"J Clin Pharmacol"},{"key":"BF6500359_CR36","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1172\/JCI915","volume":"101","author":"L Iyer","year":"1998","unstructured":"Iyer L, King CD, Roy SK, Whitington PR, Tephly TR, Coffmann B et al. Genetic predisposition to the metabolism of irinotecan: role of UGT1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 1998; 101: 847\u2013854.","journal-title":"J Clin Invest"},{"key":"BF6500359_CR37","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/S0009-9236(99)70078-0","volume":"65","author":"L Iyer","year":"1999","unstructured":"Iyer L, Hall D, Das S, Mortell MA, Ramirez J, Kim S et al. Phenotype\u2013genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promotor polymorphism. Clin Pharmacol Ther 1999; 65: 576\u2013582.","journal-title":"Clin Pharmacol Ther"},{"key":"BF6500359_CR38","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1192\/bjp.182.3.267","volume":"182","author":"JC Martin-Escudero","year":"2003","unstructured":"Martin-Escudero JC, Duenas-Laita A, Perez-Castrillon JL, Herrreros-Fernandez V . Olanzapine toxicity in unconjugated hyperbilirubinemia (Gilbert's syndrome). Br J Psychol 2003; 182: 267.","journal-title":"Br J Psychol"},{"key":"BF6500359_CR39","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/sj.tpj.6500221","volume":"4","author":"TM Danoff","year":"2004","unstructured":"Danoff TM, Campbell DA, McCarthy LC, Lewis KF, Repasch MH, Saunders AM et al. A Gilbert's syndrome UGT1A1 variant confers susceptibility to tranilast-induced hyperbilirubinemia. Pharmacogenomics J 2004; 4: 49\u201353.","journal-title":"Pharmacogenomics J"},{"key":"BF6500359_CR40","doi-asserted-by":"publisher","first-page":"12671","DOI":"10.1073\/pnas.231140698","volume":"98","author":"SD Zucker","year":"2001","unstructured":"Zucker SD, Qin X, Rouster SD, Yu F, Green RM, Keshavan P et al. Mechanism of indinavir-induced hyperbilirubinemia. Proc Natl Acad Sci USA 2001; 98: 12671\u201312676.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF6500359_CR41","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00228-003-0718-8","volume":"60","author":"A Jetter","year":"2004","unstructured":"Jetter A, Kinzig-Schippers M, Illauer M, Hermann R, Erb K, Borlak J et al. Phenotyping of N-acetyltransferase type 2 by caffeine from uncontrolled dietary exposure. Eur J Clin Pharmacol 2004; 60: 17\u201321.","journal-title":"Eur J Clin Pharmacol"},{"key":"BF6500359_CR42","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/clpt.1991.82","volume":"49","author":"BK Tang","year":"1991","unstructured":"Tang BK, Kadar D, Qian L, Iriah J, Yip J, Kalow W . Caffeine as a metabolic probe: validation of its use for acetylator phenotyping. Clin Pharmacol Ther 1991; 49: 648\u2013657.","journal-title":"Clin Pharmacol Ther"},{"key":"BF6500359_CR43","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S0378-4347(00)00272-3","volume":"748","author":"NG Knebel","year":"2000","unstructured":"Knebel NG, Grieb S, Leisenheimer S, Locher M . Determination of retigabine and its acetyl metabolite in biological matrices by on-line solid-phase extraction (column switching) liquid chromatography with tandem mass spectrometry. J Chromatogr B Biomed Sci Appl 2000; 748: 97\u2013111.","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"BF6500359_CR44","volume-title":"Clinical Pharmacokinetics: Concepts and Applications","author":"M Rowland","year":"1995","unstructured":"Rowland M, Tozer TN . Clinical Pharmacokinetics: Concepts and Applications, 3rd edn. Williams & Wilkins: Baltimore, MD, 1995."},{"unstructured":"FUNCALC. Collection of functions for noncompartmental Excel-based pharmacokinetic evaluations. Version 1.23, ASTA Medica, Feb 28, 2001.","key":"BF6500359_CR45"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/6500359.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/6500359","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/6500359.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:55:57Z","timestamp":1736211357000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6500359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,10]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,5,1]]}},"alternative-id":["BF6500359"],"URL":"https:\/\/doi.org\/10.1038\/sj.tpj.6500359","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"type":"print","value":"1470-269X"},{"type":"electronic","value":"1473-1150"}],"subject":[],"published":{"date-parts":[[2006,1,10]]},"assertion":[{"value":"15 August 2005","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2005","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2005","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2006","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}